Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Accounts Payables (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Accounts Payables for 3 consecutive years, with $5.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Accounts Payables rose 95.04% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Sep 2024, up 95.04%, and an annual FY2023 reading of $551000.0, down 86.75% over the prior year.
  • Accounts Payables was $5.0 million for Q3 2024 at Oramed Pharmaceuticals, up from $3.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.0 million in Q3 2024 and bottomed at $551000.0 in Q4 2023.
  • Average Accounts Payables over 3 years is $3.0 million, with a median of $3.5 million recorded in 2022.
  • The sharpest move saw Accounts Payables plummeted 86.75% in 2023, then surged 320.65% in 2024.
  • Year by year, Accounts Payables stood at $4.2 million in 2022, then tumbled by 86.75% to $551000.0 in 2023, then surged by 806.53% to $5.0 million in 2024.
  • Business Quant data shows Accounts Payables for ORMP at $5.0 million in Q3 2024, $3.5 million in Q2 2024, and $1.3 million in Q1 2024.